PubMed:17261671 / 1080-1256
Annnotations
PubMed_ArguminSci
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T5 | 0-176 | DRI_Background | denotes | Together, these various observations have stimulated intense interest in PPARs as therapeutic targets and led to large-scale cardiovascular end-point trials with PPAR agonists. |
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T6 | 0-176 | Sentence | denotes | Together, these various observations have stimulated intense interest in PPARs as therapeutic targets and led to large-scale cardiovascular end-point trials with PPAR agonists. |
T6 | 0-176 | Sentence | denotes | Together, these various observations have stimulated intense interest in PPARs as therapeutic targets and led to large-scale cardiovascular end-point trials with PPAR agonists. |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T6 | 0-176 | Sentence | denotes | Together, these various observations have stimulated intense interest in PPARs as therapeutic targets and led to large-scale cardiovascular end-point trials with PPAR agonists. |
T6 | 0-176 | Sentence | denotes | Together, these various observations have stimulated intense interest in PPARs as therapeutic targets and led to large-scale cardiovascular end-point trials with PPAR agonists. |
UBERON-AE
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-UBERON-AE-B_T2 | 119-124 | http://purl.obolibrary.org/obo/UBERON_0002542 | denotes | scale |
performance-test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-UBERON-AE-B_T2 | 119-124 | http://purl.obolibrary.org/obo/UBERON_0002542 | denotes | scale |